m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01139)
Name
CYC-800
Status
Preclinical
Structure
3D MOL
2D MOL
Formula
C21H25FO8
InChI
1S/C15H13FO2.C6H12O6/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11;7-1-2(8)4(10)6(12)5(11)3(1)9/h2-10H,1H3,(H,17,18);1-12H/t10-;/m1./s1
InChIKey
XXWQLQXGYRVJNJ-HNCPQSOCSA-N
PubChem CID
24759764
TTD Drug ID
D0WZ4J
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Polo-like kinase 1 (PLK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Polo-like kinase 1 (PLK1) is a therapeutic target for CYC-800. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYC-800 through regulating the expression of Polo-like kinase 1 (PLK1). [1], [2]
References
Ref 1 METTL3-mediated m(6)A modification regulates cell cycle progression of dental pulp stem cells. Stem Cell Res Ther. 2021 Mar 1;12(1):159. doi: 10.1186/s13287-021-02223-x.
Ref 2 Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. doi: 10.1634/theoncologist.2009-0010. Epub 2009 May 27.